For research use only. Not for therapeutic Use.
PQR530（Cat No.:I020123）is a dual inhibitor of the PI3K and mTOR pathways, both crucial for cell growth, survival, and metabolism. By targeting both PI3K and mTOR, PQR530 effectively disrupts cancer cell proliferation and survival, making it a promising candidate for cancer treatment. Its ability to inhibit multiple isoforms of PI3K enhances its therapeutic potential, particularly in tumors with hyperactivated PI3K/mTOR signaling. Preclinical studies have shown its efficacy in reducing tumor growth, and it is being investigated for its potential in treating various solid tumors and hematologic malignancies.
| Catalog Number | I020123 |
| CAS Number | 1927857-61-1 |
| Molecular Formula | C₁₈H₂₃F₂N₇O₂ |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | 4-(difluoromethyl)-5-[4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]pyridin-2-amine |
| InChI | InChI=1S/C18H23F2N7O2/c1-11-10-29-7-4-27(11)18-24-16(13-9-22-14(21)8-12(13)15(19)20)23-17(25-18)26-2-5-28-6-3-26/h8-9,11,15H,2-7,10H2,1H3,(H2,21,22)/t11-/m0/s1 |
| InChIKey | SYKBZXMKAPICSO-NSHDSACASA-N |
| SMILES | CC1COCCN1C2=NC(=NC(=N2)N3CCOCC3)C4=CN=C(C=C4C(F)F)N |
| Reference | [1]. Denise Rageot, et al. Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. Cancer Res 2017;77(13 Suppl).<br>[2]. Rageot D, et al. (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. J Med Chem. 2019;62(13):6241-6261. |
